



**References**

Verlohren, S. et al. (2010). *Am J Obstet Gynecol* 202(2), 161.e1-161.e11.  
 Verlohren, S. et al. (2014). *Hypertension* 63(2), 346-52.  
 Zeisler, H. et al. (2016). *N Engl J Med* 374, 13-22.  
 Elecsys® sFlt-1 (Mar 2017) and Elecsys® PIGF package insert (Nov 2017). Roche Diagnostics Documentation, Basel.

# Roche Elecsys® sFlt-1/PIGF ratio

## *Aid in diagnosis and prediction of preeclampsia<sup>1</sup>*

Determination of the sFlt-1/PIGF ratio **from gestational week 20+0**

**Patient profile:**<sup>2-5</sup>

**1**

Clinical suspicion for preeclampsia

or

**2**

Pathological Doppler-ultrasound of uterine arteries

or

**3**

**One of the following risk factors:**

- PE in a previous pregnancy
- Chronic hypertension
- Preexisting kidney disease
- Diabetes mellitus
- Identified as high risk in the PE 1<sup>st</sup> trimester screening

Sample material: serum

### References

- <sup>1</sup> Elecsys® PIGF and Elecsys® s-Flt1 package inserts, 2018.
- <sup>2</sup> Rolnik et al. (2017). *N Engl J Med*. 377(7), 613-622 (ASPREE).
- <sup>3</sup> O’Gorman, N. et al. (2016). *Am J Obstet Gynecol*. 214(1), 103.e1-103.e12.
- <sup>4</sup> Tsiakkas, A. et al. (2016). *Ultrasound Obstet Gynecol* 47, 472-477.
- <sup>5</sup> O’Gorman, N. et al. (2017). *Ultrasound Obstet Gynecol* 49, 756-760.